Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation

Naomi S H de Jong; Steven T Leach; Andrew S Day

doi:10.1007/s10620-006-9449-x

Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation

Dig Dis Sci. 2007 Sep;52(9):2029-36. doi: 10.1007/s10620-006-9449-x. Epub 2007 Apr 4.

Authors

Naomi S H de Jong¹, Steven T Leach, Andrew S Day

Affiliation

¹ School of Women's and Children's Health, University of New South Wales, Sydney, Australia.

PMID: 17406842
DOI: 10.1007/s10620-006-9449-x

Abstract

Exclusive enteral nutrition using polymeric formula (PF) is a well-established therapeutic option for active Crohn's disease; however, its mechanisms of action are unknown. We investigated the anti-inflammatory effects of PF in an in vitro model of epithelial cell inflammation. PF did not affect cell viability over a range of dilutions, but when PF was added to the culture medium the interleukin (IL)-8 response to proinflammatory stimuli was significantly reduced. This effect was due to PF acting directly on the cells as the IL-8 response was still reduced when PF was separated from the proinflammatory stimuli in a 2-compartment system. In the presence of PF, nuclear factor (NF)-kappaB nuclear migration was not inhibited; however, IkappaBalpha degradation was delayed. PF has direct anti-inflammatory effects upon immortalized colonic enterocytes. Therefore PF may, in part, modulate gut inflammation by directly reducing the inflammatory response of the intestinal epithelium.

MeSH terms

Blotting, Western
Cell Survival / drug effects
Cells, Cultured
Culture Media
Drug Combinations
Enterocytes / drug effects
Enterocytes / metabolism
Enterocytes / pathology
Enzyme-Linked Immunosorbent Assay
HT29 Cells / drug effects
HT29 Cells / metabolism
HT29 Cells / pathology
Humans
Immunoglobulin G / therapeutic use*
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / metabolism
Inflammatory Bowel Diseases / pathology
Interleukin-1alpha / therapeutic use*
Interleukin-8 / metabolism
Lipopolysaccharides / therapeutic use*
NF-kappa B / drug effects
NF-kappa B / metabolism
Transcription Factor RelA / therapeutic use*
Transforming Growth Factor beta / therapeutic use*
Tumor Necrosis Factor-alpha / therapeutic use*

Substances

Culture Media
Drug Combinations
Immunoglobulin G
Interleukin-1alpha
Interleukin-8
Lipopolysaccharides
NF-kappa B
TONSL protein, human
Transcription Factor RelA
Transforming Growth Factor beta
Tumor Necrosis Factor-alpha